News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Jul 28, 2010
• Spanish health authorities grant regulatory approval for Sativex®, the first new treatment for MS-related spasticity in decades • Launch expected 4th Quarter 2010 • Application submitted
Jul 27, 2010
Porton Down, UK, 27 July 2010: GW Pharmaceuticals plc (AIM: GWP) today announces the appointment of Tom Lynch as a non-executive director with immediate effect.
Jul 02, 2010
In response to a story in a regional UK media outlet yesterday, GW wishes to make the following clarification:
Jun 30, 2010
London, UK; Tokyo, Japan; June 30 2010: GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd.
Jun 22, 2010
Porton Down, UK, 22 June 2010: GW Pharmaceuticals plc (AIM: GWP) announces that its Managing Director, Justin Gover will be presenting at the 5th Annual Piper Jaffray Europe Healthcare Conference in
Jun 21, 2010
Porton Down, UK, 21 June 2010: GW Pharmaceuticals plc (GWP:AIM) today announces the UK launch of Sativex®, its Oromucosal Spray for the treatment of spasticity due to Multiple Sclerosis (MS).
May 20, 2010
Porton Down, UK, 20 May 2010: GW Pharmaceuticals plc (AIM: GWP), the specialty pharmaceutical company focused on cannabinoid science, announces its interim results for the six months ended 31 March
Mar 23, 2010
Porton Down, UK; 23 March 2010: GW Pharmaceuticals plc (AIM: GWP) today announced preliminary results of a Phase IIb dose-ranging trial evaluating the efficacy and safety of Sativex® in the treatmen
Mar 18, 2010
Sativex Update - UK and Spanish regulators confirm no major issues - Approvals expected Q2 2010

Pages